Mind the gap: Models in multiple species needed for therapeutic development in Huntington's disease

Movement Disorders

Volumn 29, Issue 11, 2014, Pages 1397-1403

  Howland, David S ^a   Munoz Sanjuan, Ignacio ^a  

^a CHDI MANAGEMENT CHDI FOUNDATION   (United States)

Author keywords

Animal model; Huntingtin; Minipig; Nonhuman primate; Sheep

Indexed keywords

HTT PROTEIN, HUMAN; NERVE PROTEIN;

ANIMAL; DISEASE MODEL; GENETICS; HUMAN; HUNTINGTON DISEASE; PROCEDURES; SPECIES DIFFERENCE; TRANSLATIONAL RESEARCH; TRINUCLEOTIDE REPEAT;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; SPECIES SPECIFICITY; TRANSLATIONAL MEDICAL RESEARCH; TRINUCLEOTIDE REPEATS;

EID: 84907939186     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26008     Document Type: Article

References (39)

1. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 2007;26:1-13.
2. Perrin S. Preclinical research: make mouse studies work. Nature 2014;507:423-425.
3. Landis SC, Amara SG, Asadullah K, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012;490:187-191.
4. Menalled LM, Lutz C, Ramboz S, Brunner D, Lager B, Noble S, Howland D. A Field Guide to Working With Mouse Models of Huntington's Disease. The Jackson Laboratory, 2014. Available from: http://chdifoundation.org/wpcontent/uploads/HD_Field_Guide_040414.pdf. Accessed on 1 May 2014.
5. Morton AJ, Howland DS. Large genetic animal models of Huntington's disease. J Huntington's Dis 2013;2:3-19.
6. Yang D, Wang CE, Zhao B, et al. Expression of Huntington's disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Hum Mol Genet 2010;19:3983-3994.
7. Munoz-Sanjuan I, Bates GP. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J Clin Invest 2011;121:476-483.
8. Stanek LM, Sardi SP, Mastis B, et al. Silencing mutant Huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. Hum Gene Therapy 2014;25:461-474.
9. Sah DW, Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest 2011;121:500-507.
10. Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012;74:1031-1044.
11. Yu D, Pendergraff H, Liu J, et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 2012;150:895-908.
12. McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, Davidson BL. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther 2011;19:2152-2162.
13. Nguyen GD, Gokhan S, Molero AE, Mehler MF. Selective roles of normal and mutant huntingtin in neural induction and early neurogenesis. PLoS One 2013;8:e64368.
14. Molero AE, Gokhan S, Gonzalez S, Feig JL, Alexandre LC, Mehler MF. Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease. Proc Natl Acad Sci U S A 2009;106:21900-21905.
15. Woda JM, Calzonetti T, Hilditch-Maguire P, Duyao MP, Conlon RA, MacDonald ME. Inactivation of the Huntington's disease gene (Hdh) impairs anterior streak formation and early patterning of the mouse embryo. BMC Dev Biol 2005;5:17.
16. Hoffmann R, Stüwe SH, Goetze O, et al. Progressive hepatic mitochondrial dysfunction in premanifest Huntington's disease. Mov Disord 2014;29:831-834.
17. Ismailoglu I, Chen Q, Popowski M, Yang L, Gross SS, Brivanlou AH. Huntingtin protein is essential for mitochondrial metabolism, bioenergetics and structure in murine embryonic stem cells. Dev Biol 2014;391:230-240.
18. Waters CW, Varuzhanyan G, Talmadge RJ, Voss AA. Huntington disease skeletal muscle is hyperexcitable owing to chloride and potassium channel dysfunction. Proc Natl Acad Sci U S A 2013;110:9160-9165.
19. Lin CY, Hsu YH, Lin MH, et al. Neurovascular abnormalities in humans and mice with Huntington's disease. Exp Neurol 2013;250:20-30.
20. Baxa M, Hruska-Plochan M, Juhas S, et al. A transgenic minipig model of Huntington's disease. J Huntington's Dis 2013;2:47-68.
21. Jacobsen JC, Bawden CS, Rudiger SR, et al. An ovine transgenic Huntington's disease model. Hum Mol Genet 2010;19:1873-1882.
22. Yang SH, Cheng PH, Banta H, et al. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 2008;453:921-924.
23. Chan AW, Xu Y, Jiang J, et al. A two years longitudinal study of a transgenic Huntington disease monkey. BMC Neurosci 2014;15:36.
24. Reid SJ, Patassini S, Handley RR, et al. Further molecular characterisation of the OVT73 transgenic sheep model of Huntington's disease identifies cortical aggregates. J Huntington's Dis 2013;2:279.
25. Morton AJ, Rudiger SR, Wood NI, et al. Early and progressive circadian abnormalities in Huntington's disease sheep are unmasked by social environment. Hum Mol Genet 2014;23:3375-3383.
26. Gieling E, Wehkamp W, Willigenburg R, Nordquist RE, Ganderup NC, van der Staay FJ. Performance of conventional pigs and Göttingen miniature pigs in a spatial holeboard task: effects of the putative muscarinic cognition impairer. Behav Brain Funct 2013;9:4.
27. Morton AJ, Avanzo L. Executive decision-making in the domestic sheep. PLoS One 2011;6:e15752.
28. Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013;31:397-405.
29. Carlson DF, Tan W, Lillico SG, et al. Efficient TALEN-mediated gene knockout in livestock. Proc Natl Acad Sci U S A 2012;109:17382-17387.
30. Tan W, Carlson DF, Lancto CA, Garbe JR, Webster DA, Hackett PB, Fahrenkrug SC. Efficient nonmeiotic allele introgression in livestock using custom endonucleases. Proc Natl Acad Sci U S A 2013;110:16526-16531.
31. Niu Y, Shen B, Cui Y, et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 2014;156:836-843.
32. Antoniades CA, Watts C. Huntington's disease and cell therapies: past, present, and future. Methods Mol Biol 2013;1010:19-32.
33. Benraiss A, Goldman SA. Cellular therapy and induced neuronal replacement for Huntington's disease. Neurotherapeutics 2011;8:577-590.
34. Palfi S, Brouillet E, Jarraya B, et al. Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. N Mol Ther 2007;15:1444-1451.
35. Mashiko H, Yoshida AC, Kikuchi SS, et al. Comparative anatomy of marmoset and mouse cortex from genomic expression. J Neurosci 2012;32:5039-5053.
36. Rosa MG, Tweedale R. Brain maps, great and small: lessons from comparative studies of primate visual cortical organization. Philos Trans R Soc Lond B Biol Sci 2005;360:665-691.
37. Kishi N, Sato K, Sasaki E, Okano H. Common marmoset as a new model animal for neuroscience research and genome editing technology. Dev Growth Differ 2014;56:53-62.
38. Quarrell O, O'Donovan KL, Bandmann O, Strong M. The prevalence of juvenile Huntington's disease: a review of the literature and meta-analysis. PLoS Curr 2012;4:e4f8606b742ef3. doi: 10.1371/4f8606b742ef3.
39. Siesling S, Vegter-van der Vlis M, Roos RAC. Juvenile Huntington disease in the Netherlands. Paediatr Neurol 1997;17:37-43.